The average one-year price target for Genmab A (NasdaqGS:GMAB) has been revised to $55.27 / share. This is a decrease of ...

This article first appeared on GuruFocus. Genmab AS (NASDAQ:GMAB) is set to release its Q3 2025 earnings on Nov 6, 2025. The ...

In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...

An update from Genmab ( ($GMAB) ) is now available. On November 10, 2025, Genmab A/S announced a proposed private offering of $1.5 billion in ...

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, ...

Genmab revenue increased 21% compared to the first nine months of 2024, to $2,662 million FDA granted BTD to Rina-S ® in advanced endometrial cancer Epcoritamab Phase 3 EPCORE ® FL-1 trial met dual ...

Danish biotech Genmab reported a 25% rise in its total revenue to $1.02 billion during the third quarter of 2025, ahead of ...

Medicxi Announces €500 Million Fund VNew fund will continue Medicxi’s successful asset-centric company creation and investment strategy. LONDON, UK — November 14, 2025 — Medicxi, a leading European ...

November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab's proposed acquisition of Merus N.V. (Merus)Genmab revenue increased ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Media ReleaseCOPENHAGEN, Denmark; November 5, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will ...

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...